Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etofibrate
- Development stage
- Phase 3
- Lead developer
- Merz Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Etofibrate** is an oral, small-molecule lipid-modifying fibrate used for hyperlipidemia, particularly mixed hyperlipidemia and hypertriglyceridemia. It is a single covalent ethylene-glycol diester combining a clofibrate-derived moiety with nicotinic acid, designed to undergo hydrolysis and gradually provide fibrate and niacin pharmacology. Its principal lipid-lowering activity is attributed to fibrate-mediated activation of peroxisome proliferator-activated receptor alpha, with niacin-related hydroxycarboxylic acid receptor 2 signaling also contributing to effects on lipid metabolism. Clinical studies reported reductions in triglycerides, total cholesterol, LDL cholesterol, and lipoprotein(a), with increased HDL cholesterol; it was also investigated in diabetic retinopathy. It has been marketed as Lipo-Merz and Tricerol. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Etofibrate))
- Brand names
- Lipo-MerzLipo-Merz RetardTricerolTricerol A.P.
- Other names
- ethofibrateetofibratoetofibratum2-[2-(4-chlorophenoxy)-2-methylpropanoyloxy]ethyl nicotinate
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on etofibrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etofibrate.